The twin designations are designed to speed up the development and review of promising medicines targeting serious conditions with high unmet need
SPARC enters definitive agreement to monetise rare paediatric disease PRV, unlocking capital for R&D and strategic growth
Our company remains focused on advancing monoclonal antibody therapeutics for solid tumors, with a clear emphasis on combination immunotherapy strategies
Approval for generic Semaglutide Injection strengthens CDMO partnership, enabling scalable supply from OneSource’s US FDA-approved Bengaluru facility
After Phase 3 results show major hair regrowth gains
The company receives approval for blood-based test enabling objective differentiation of schizophrenia and bipolar disorder
_256_384.png)
The company plans a phased expansion across India, focusing initially on metro cities and early-adoption hubs
Deploys $40 million in Hyderabad; advances APIs, peptides, and global small molecule capabilities
The submission is backed by positive results from the Phase 3 AFFIRM study
The lens received U.S. Food and Drug Administration (FDA) market authorization via the De Novo pathway in late 2025
Subscribe To Our Newsletter & Stay Updated
